Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuo Hamamoto

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Japanese Journal of Clinical Oncology|February 27, 2010
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506Hiroshi Ishii, Junji Furuse, Narikazu Boku, et al.
Japanese Journal of Clinical Oncology|May 14, 2010
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancerToshihiko Doi, Narikazu Boku, Ken Kato, et al.
Molecular and Clinical Oncology|January 19, 2019
Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case reportYu Aoki, Yasuo Hamamoto, Aya Ugamura, et al.
Gastrointestinal Endoscopy|March 30, 2002
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasmsShin'ichi Miyamoto, Manabu Muto, Yasuo Hamamoto, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 31, 2003
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing surveyHiroki Kawai, Atsushi Ohtsu, Narikazu Boku, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 19, 2011
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]Atsushi Sato, Toshihiko Doi, Narikazu Boku, et al.
Cancer Science|September 3, 2013
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinomaHiroki Hara, Makoto Tahara, Hiroyuki Daiko, et al.
Oncology Letters|June 18, 2016
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)Tomohiro Nishi, Yasuo Hamamoto, Michitaka Nagase, et al.
Journal of Clinical Pharmacology|January 3, 2014
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphismsMitsukuni Suenaga, Nozomu Fuse, Tatsuro Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancerToshihiko Doi, Kei Muro, Narikazu Boku, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Japanese Journal of Clinical Oncology|February 27, 2010
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506Hiroshi Ishii, Junji Furuse, Narikazu Boku, et al.
Japanese Journal of Clinical Oncology|May 14, 2010
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancerToshihiko Doi, Narikazu Boku, Ken Kato, et al.
Molecular and Clinical Oncology|January 19, 2019
Early administration of systemic chemotherapy should be considered for scirrhous gastric cancer: A case reportYu Aoki, Yasuo Hamamoto, Aya Ugamura, et al.
Gastrointestinal Endoscopy|March 30, 2002
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasmsShin'ichi Miyamoto, Manabu Muto, Yasuo Hamamoto, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 31, 2003
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing surveyHiroki Kawai, Atsushi Ohtsu, Narikazu Boku, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 19, 2011
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)]Atsushi Sato, Toshihiko Doi, Narikazu Boku, et al.
Cancer Science|September 3, 2013
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinomaHiroki Hara, Makoto Tahara, Hiroyuki Daiko, et al.
Oncology Letters|June 18, 2016
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)Tomohiro Nishi, Yasuo Hamamoto, Michitaka Nagase, et al.
Journal of Clinical Pharmacology|January 3, 2014
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphismsMitsukuni Suenaga, Nozomu Fuse, Tatsuro Yamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancerToshihiko Doi, Kei Muro, Narikazu Boku, et al.
Pageof 13